Revance Therapeutics adds Chris Nolet to Board of Directors as Chair of Audit Committee

– USA, CA –   Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Chris Nolet to the company’s Board of Directors.

Mr. Nolet brings deep experience as a long-time audit partner and business advisor in the Life Sciences industry and will provide strong leadership as he also assumes the role of Chair of the Revance Audit Committee, planned for mid-August.

“Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Board of Directors,” said Dan Browne, President, and CEO of Revance. “Chris’s leadership roles with Ernst & Young (EY) Life Sciences Industry Group and the California Life Sciences Industry Association (CLSA) among others, bring invaluable economic, operational, and policy expertise to the company. As Chair of the Audit Committee, he will provide valuable oversight of our corporate accounting and financial reporting processes, internal controls, financial reporting, and audit functions, as we progress towards commercial company status.”

About Chris Nolet

Mr. Nolet is the former West Region Life Sciences Industry Leader & Partner at EY, retiring in June of 2019 after more than 38 years in the profession. In addition to serving clients, his responsibilities included leading West Region EY Life Sciences Industry Group, and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. He currently serves on both the Executive Committee and Audit Committee (Chair) of CLSA, and is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization. Prior to joining EY, Mr. Nolet was​ ​a partner at PricewaterhouseCoopers where he led the Life Sciences practice in the western U.S.

“I have been very fortunate to work with the full range of life sciences companies, from rapidly growing VC-backed startups to Fortune 100 companies, and understand the underpinnings of a successful commercial biotech business,” said Mr. Nolet. “I am elated to be a part of the Revance board as the company prepares to meaningfully transform patient experiences and disrupt the $4.5 billion global neuromodulator industry with its innovative science.

He has a B.S. in Accounting from San Diego State University and ​is​ a Certified Public Accountant in California.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company focused on developing transformative neuromodulators to address a broad spectrum of aesthetic and therapeutic conditions. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), utilizes a unique proprietary peptide excipient technology combined with highly purified botulinum toxin type A to produce a novel, long-acting neuromodulator. In aesthetics, Revance successfully completed its Phase 3 program for DAXI in glabellar (frown) lines and is currently pursuing U.S. regulatory approval in 2020, while also running two separate Phase 2 studies in forehead lines and lateral canthal lines (crow’s feet). In therapeutics, DAXI is being studied in three indications, including a Phase 3 trial in cervical dystonia, a Phase 2 trial in adult upper limb spasticity, and a Phase 2 trial in plantar fasciitis, with plans to also study migraine. Beyond DAXI, Revance also has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.

For more information,

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.